Table II.
Laboratory evaluation in the whole cohort and by serum LDH groups
| Entire cohort (n=1019) |
Normal serum LDH (n=610) |
High serum LDH (n=409) |
P | |
|---|---|---|---|---|
| Plasma cell compartment evaluation | ||||
| BMPCs, median (IQR) | 9 (5–15) | 8 (5–14) | 9 (5–15) | 0.52 |
| dFLC, mg/dl, median (IQR) (n=888) | 23 (9–57) | 22 (8–57) | 24 (10–60) | 0.26 |
| Labelling index (n=668) | 0 (0–0.4) | 0 (0–0.3) | 0(0–0.4) | 0.42 |
| Significant immunoparesis, N (%) (n=928) | 335 (36%) | 212 (38%) | 123 (33%) | 0.11 |
| Organ function evaluation | ||||
| Haemoglobin, g/l median (IQR) | 131 (119–144) | 132 (119–144) | 131 (118–146) | 0.94 |
| Serum albumin, g/l, median (IQR) | 29 (23–33) | 30 (24–34) | 26 (19–32) | <0.001 |
| Thyroid stimulating hormone, u/ml, median (IQR) | 2.8 (1.8–4.5) | 2.6 (1.7–4.2) | 3.1 (2.1–4.7) | <0.001 |
| Cardiac amyloidosis population | ||||
| NT-proBNP, pg/ml, median (IQR) | 3766 (1333–8934) | 2385 (999–5128) | 6164 (2166–12691) | <0.001 |
| Troponin T, ng/ml, median (IQR) | 0.04 (0.01–0.1) | 0.02 (<0.01–0.05) | 0.08 (0.03–0.15) | <0.001 |
| Renal amyloidosis population | ||||
| eGFR, ml/min/1.73 m2, median (IQR) | 60 (41–78) | 66 (49–81) | 53 (30–70) | <0.001 |
| Proteinuria, g/24 h, median (IQR) | 4.8 (1.8–8.2) | 4.1 (1.8–7.4) | 5.3 (2.0–9.4) | 0.008 |
| Hepatic amyloidosis population | ||||
| Alkaline phosphatase, xUNL, median (IQR) | 2.4 (1.7–4.5) | 2.4 (1.6–4.2) | 2.6 (1.7–4.8) | 0.14 |
| Total bilirubin, µmol/l, median (IQR) | 13.7 (8.6–25.7) | 13.7 (8.6–23.9) | 13.7 (8.6–29.1) | 0.71 |
Abbreviations: BMPCs, bone marrow plasma cells; dFLC, difference between involved and uninvolved light chains; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LDH, Lactate dehydrogenase; NT-proBNP, N-terminal pro b-type natriuretic peptide; ULN, upper limit of normal;.